Fintel reports that on March 26, 2024, OTR Global upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Mixed to Positive.

Analyst Price Forecast Suggests 0.47% Upside

As of March 11, 2024, the average one-year price target for Edwards Lifesciences is 93.60. The forecasts range from a low of 72.72 to a high of $110.25. The average price target represents an increase of 0.47% from its latest reported closing price of 93.16.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Edwards Lifesciences is 6,579MM, an increase of 9.56%. The projected annual non-GAAP EPS is 2.94.

What is the Fund Sentiment?

There are 2097 funds or institutions reporting positions in Edwards Lifesciences. This is a decrease of 225 owner(s) or 9.69% in the last quarter. Average portfolio weight of all funds dedicated to EW is 0.26%, a decrease of 30.20%. Total shares owned by institutions decreased in the last three months by 7.57% to 540,639K shares. The put/call ratio of EW is 0.89, indicating a bullish outlook.

What are Other Shareholders Doing?

Alliancebernstein holds 19,089K shares representing 3.17% ownership of the company. In it's prior filing, the firm reported owning 22,742K shares, representing a decrease of 19.14%. The firm decreased its portfolio allocation in EW by 28.63% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 19,054K shares representing 3.17% ownership of the company. In it's prior filing, the firm reported owning 18,932K shares, representing an increase of 0.64%. The firm decreased its portfolio allocation in EW by 1.01% over the last quarter.

Brown Advisory holds 18,181K shares representing 3.02% ownership of the company. In it's prior filing, the firm reported owning 15,133K shares, representing an increase of 16.77%. The firm decreased its portfolio allocation in EW by 37.92% over the last quarter.

Bank of New York Mellon holds 17,328K shares representing 2.88% ownership of the company. In it's prior filing, the firm reported owning 17,609K shares, representing a decrease of 1.62%. The firm decreased its portfolio allocation in EW by 88.94% over the last quarter.

Wellington Management Group Llp holds 16,828K shares representing 2.80% ownership of the company. In it's prior filing, the firm reported owning 16,434K shares, representing an increase of 2.34%. The firm decreased its portfolio allocation in EW by 84.90% over the last quarter.

Edwards Lifesciences Background Information
(This description is provided by the company.)

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.